RegeneRx Gets $3m Grant For Heart Attack Drug Development
RGN-352 is an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tß4, for patients who have suffered an acute myocardial infarction, or AMI or heart
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
eClinicalWorks’ unified solutions allow patient data to be shared within a network of physicians, while streamlining workflow, enhancing charge capture and eliminating the paper charts. More than 40,000